Clinical Cancer Research 2014-04-29

Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.

Lucia Banci, Diego Brancaccio, Simone Ciofi-Baffoni, Rebecca Del Conte, Ravisekhar Gadepalli, Maciej Mikolajczyk, Sara Neri, Mario Piccioli, Julia Winkelmann

文献索引:Clin. Cancer Res. 2(6) , 973-80, (1996)

全文:HTML全文

摘要

In this work, we demonstrate a protective effect conferred by the human multidrug resistance gene (MDR1) to populations of the murine hematopoietic system against the toxic effects of bisantrene, a novel intercalating cytotoxic agent under investigation as an anticancer agent. In vitro, MDR1-expressing cell lines are highly cross-resistant to bisantrene, and low levels of P-glycoprotein (the MDR1 gene product cell surface protein) confer resistance to the drug. MDR1-positive mice were generated after transplantation of bone marrow cells (BMC) transduced in vitro with a MDR1 retrovirus. Control mice were transplanted with BMC transduced with the neomycin resistance gene. Administration of a single i.v. dose of 50 mg/kg of bisantrene resulted in a decrease of the total WBC count of approximately 40%. In contrast, a decrease of the total WBC count of only 17% was observed in mice transplanted with MDR1-transduced BMC. Immunofluorescence studies with cell lineage-specific monoclonal antibodies showed that bisantrene was specifically toxic for B lymphocytes and macrophages. Double-staining with MRK16 (a monoclonal antibody specific for P-glycoprotein) demonstrated that a single dose of bisantrene increased the relative number of MDR1-transduced positive B cells, macrophages, and (to some extent) granulocytes when compared to the number found in MDR1-untreated mice or the bisantrene-treated neomycin-transduced control mice. These results provide in vivo evidence that bisantrene is a hematotoxic drug capable of selecting for MDR1-transduced hematopoietic cells. Bisantrene might be useful for gene therapy as an in vivo selective agent for cells transduced with MDR1 vectors that also coexpress therapeutic genes of interest.


相关化合物

  • 比生群

相关文献:

In vitro effects of bisantrene on fresh clonogenic leukemia cells: a preliminary study on 15 cases.

1990-01-01

[Haematologica 75(6) , 527-31, (1990)]

Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.

1991-01-01

[Med. Pediatr. Oncol. 19(2) , 126-8, (1991)]

Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.

1998-01-20

[Bioorg. Med. Chem. Lett. 8(2) , 121-6, (1998)]

Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.

1990-08-01

[Invest. New Drugs 8(3) , 313-5, (1990)]

Bisantrene in relapsed and refractory acute myelogenous leukemia.

1993-02-01

[Leuk. Lymphoma 9(3) , 217-20, (1993)]

更多文献...